Acadia Pharmaceuticals (ACAD) Depreciation & Amortization (CF) (2010 - 2026)

Acadia Pharmaceuticals' Depreciation & Amortization (CF) history runs 17 years deep, the most recent figure standing at $271000.0 for Q1 2026.

• In Q1 2026, Depreciation & Amortization (CF) rose 18.34% year-over-year to $271000.0; the TTM figure through Mar 2026 stood at $942000.0 (up 3.86% YoY), while the FY2025 annual figure was $900000.0, down 2.17% from the prior year.
• Depreciation & Amortization (CF) was $271000.0 for Q1 2026 at Acadia Pharmaceuticals, up from $231000.0 in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $516000.0 in Q1 2022 to a low of $213000.0 in Q2 2025.
• Historically, Depreciation & Amortization (CF) has averaged $326470.6 across 5 years, with a median of $271000.0 in 2026.
• The sharpest annual moves came in 2024 and 2026: Depreciation & Amortization (CF) tumbled 43.78% in 2024, then increased 18.34% in 2026.
• A 5-year view of Depreciation & Amortization (CF) shows it stood at $463000.0 in 2022, then plunged by 41.25% to $272000.0 in 2023, then retreated by 16.91% to $226000.0 in 2024, then gained by 2.21% to $231000.0 in 2025, then grew by 17.32% to $271000.0 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $271000.0 (Q1 2026), $231000.0 (Q4 2025), and $227000.0 (Q3 2025), per Business Quant data.